<p><h1>Pharmaceutical Cannabis Market Insights, Market Players and Forecast Till 2031</h1></p><p><strong>Pharmaceutical Cannabis Market Analysis and Latest Trends</strong></p>
<p><p>Pharmaceutical cannabis, also known as medical cannabis or medical marijuana, refers to the use of cannabis for medical purposes. It involves the utilization of cannabis and its extracts as a treatment for various health conditions, including chronic pain, multiple sclerosis, epilepsy, cancer-related symptoms, and others.</p><p>The global pharmaceutical cannabis market has witnessed significant growth in recent years and is expected to continue to grow at a compound annual growth rate (CAGR) of 6.3% during the forecast period. This growth can be attributed to several factors, including the increasing adoption of cannabis for medical purposes, the legalization of medical cannabis in several countries, and the growing awareness about its potential therapeutic benefits.</p><p>Furthermore, the rising prevalence of chronic diseases worldwide, such as cancer and neurological disorders, has led to an increased demand for pharmaceutical cannabis as an alternative treatment option. Additionally, the ongoing research and development activities aimed at exploring new cannabis-based therapies and the introduction of innovative delivery methods, such as oral sprays, capsules, and patches, are also driving the market growth.</p><p>Moreover, countries like Canada, the United States, Germany, and Australia have emerged as key markets for pharmaceutical cannabis, owing to the legalization efforts and the establishment of regulatory frameworks for the medical use of cannabis. These regions have witnessed a significant increase in the number of licensed producers and dispensaries, ensuring better accessibility to pharmaceutical cannabis products.</p><p>In conclusion, the pharmaceutical cannabis market is experiencing steady growth and is projected to continue expanding at a CAGR of 6.3% during the forecast period. Factors such as increasing adoption, legalization efforts, and ongoing research and development activities are driving the growth of this market.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1262199">https://www.reliableresearchreports.com/enquiry/request-sample/1262199</a></p>
<p>&nbsp;</p>
<p><strong>Pharmaceutical Cannabis Major Market Players</strong></p>
<p><p>The pharmaceutical cannabis market is witnessing rapid growth, driven by increasing acceptance of medical cannabis, growing prevalence of chronic diseases, and ongoing research and development activities. Some of the key players in this market include Canopy Growth Corporation, GW Pharmaceuticals, plc, Aurora Cannabis, Inc., Aphria, Inc., MedReleaf Corporation, Insys Therapeutics, Inc., CanniMed Therapeutics, Inc., Cara Therapeutics, Inc., and United Cannabis Corporation.</p><p>Canopy Growth Corporation is one of the largest players in the pharmaceutical cannabis market. The company has a diverse portfolio of cannabis-based products, including oils, capsules, and dried flowers. With a strong presence in both the medical and recreational cannabis markets, Canopy Growth has been experiencing significant market growth. In 2019, the company reported net revenues of CAD 366 million, representing a growth of 191% compared to the previous year.</p><p>Aurora Cannabis, Inc. is another major player in the pharmaceutical cannabis market. The company focuses on the production and distribution of medical cannabis products globally. Aurora Cannabis has experienced significant market growth, driven by its strategic acquisitions and partnerships. In 2019, the company reported net revenues of CAD 247.9 million, representing a growth of 349% compared to the previous year.</p><p>GW Pharmaceuticals, plc is a leading pharmaceutical company specialized in developing cannabinoid-based medicines. The company's flagship product, Epidiolex, is the first FDA-approved prescription medication derived from cannabis. GW Pharmaceuticals has been witnessing substantial market growth due to the increasing demand for Epidiolex. In 2019, the company reported net sales of $311.3 million, representing a growth of 209% compared to the previous year.</p><p>Aphria, Inc. is a Canadian cannabis company that has been experiencing significant market growth in both the medical and adult-use cannabis markets. The company focuses on producing high-quality cannabis products and has a strong international presence. In 2019, Aphria reported net revenues of CAD 237.1 million, representing a growth of 848% compared to the previous year.</p><p>The pharmaceutical cannabis market is expected to continue its robust growth in the coming years. Factors such as the increasing acceptance of medical cannabis, favorable regulations, and growing investment in research and development activities will drive market expansion. According to a report by Grand View Research, the global pharmaceutical cannabis market size is expected to reach $75.6 billion by 2027, growing at a CAGR of 24.4% from 2020 to 2027.</p><p>Overall, the pharmaceutical cannabis market is highly competitive, with several key players experiencing significant market growth. Canopy Growth Corporation, GW Pharmaceuticals, plc, Aurora Cannabis, Inc., and Aphria, Inc. are among the companies at the forefront of this rapidly expanding market, exhibiting strong sales revenue and positioning themselves for future growth.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Pharmaceutical Cannabis Manufacturers?</strong></p>
<p><p>The pharmaceutical cannabis market has witnessed significant growth in recent years, driven by the increasing acceptance and legalization of medical cannabis across various countries. The market is expected to continue its upward trajectory in the coming years, with a projected compound annual growth rate (CAGR) of X% from 2021 to 2026. Factors such as the expanding patient pool, growing incidences of chronic pain and neurological disorders, and the rise in research and development activities pertaining to cannabis-based pharmaceuticals are anticipated to propel the market's growth. Additionally, innovations in delivery methods, new product developments, and strategic collaborations among industry players are likely to shape the future outlook of the pharmaceutical cannabis market.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1262199">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1262199</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Pharmaceutical Cannabis Market Analysis by types is segmented into:</strong></p>
<p><ul><li>THC-dominant</li><li>CBD-dominant</li><li>Balanced THC & CBD</li></ul></p>
<p><p>Pharmaceutical cannabis market types refer to different compositions of cannabinoids in medicinal cannabis products. THC-dominant products have higher levels of tetrahydrocannabinol, the psychoactive compound responsible for the "high" effect. CBD-dominant products contain higher levels of cannabidiol, a non-psychoactive compound known for its potential therapeutic benefits. Balanced THC and CBD products have equal amounts of both compounds. These market types cater to diverse medical needs, with THC-dominant products potentially aiding pain relief and appetite stimulation, CBD-dominant products being used for anxiety and seizures, and balanced products providing a combination of effects.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1262199">https://www.reliableresearchreports.com/purchase/1262199</a></p>
<p>&nbsp;</p>
<p><strong>The Pharmaceutical Cannabis Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Cancer</li><li>Arthritis</li><li>Migraine</li><li>Epilepsy</li><li>Others</li></ul></p>
<p><p>The pharmaceutical cannabis market application encompasses various medical conditions, including cancer, arthritis, migraine, epilepsy, and others. Cannabis-based treatments have shown potential in managing symptoms and improving the quality of life for patients suffering from these ailments. Studies indicate that cannabis can reduce pain, inflammation, and seizures, making it a viable option for people with arthritis, migraines, epilepsy, and cancer-related symptoms. Furthermore, cannabis-based medicines continue to be explored for their potential in treating other medical conditions, highlighting the extensive applications of pharmaceutical cannabis in modern medicine.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Pharmaceutical Cannabis Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The global pharmaceutical cannabis market is witnessing significant growth, and it is projected to continue expanding in the coming years. North America (NA), specifically the United States (USA), is currently dominating the market due to its supportive regulatory environment and increasing acceptance of cannabis-based therapies. With a market share estimated to be around 40%, NA is expected to maintain its dominance. Asia-Pacific (APAC), propelled by countries such as China, is anticipated to experience rapid growth, with a projected market share of approximately 25%. Europe is also expected to contribute significantly, with an estimated market share of 20%.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1262199">https://www.reliableresearchreports.com/purchase/1262199</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1262199">https://www.reliableresearchreports.com/enquiry/request-sample/1262199</a></p>
<p><strong></strong></p>
<p>Check more reports on https://www.reliableresearchreports.com/</p>